- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03715946
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
This study aims to enroll 135 patients (male and female, age 18+) who are newly diagnosed with resectable, squamous cell carcinoma or undifferentiated carcinoma of the oropharynx. Survival rate and treatment response of OPSCC varies based on HPV infection status and genotype; therefore, in this study, only patients who are HPV seropositive and have HPV type 16 will be enrolled. All patients will receive the same treatment, i.e. there is no active control group.
In this trial, patients will undergo transoral surgery followed by de-intensified adjuvant radiotherapy plus nivolumab. The radiotherapy will consist of 45 or 50 Gy (depending on tumor volume) in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at a fixed dose of 240 mg over 30 minutes IV every 2 weeks during radiotherapy, and at 480 mg over 60 minutes IV every 4 weeks for 6 doses after radiotherapy. The first dose will be given prior to the first fraction of radiation (Day 1) on Day -3 (+/- 2 days), and continued every 2 weeks (+/- 2 days). Nivolumab will thus be given in weeks 2 and 4 of radiotherapy. Adjuvant nivolumab will then be given for a total of 6 additional doses after the completion of radiotherapy every 4 weeks (+/- 7 days), starting in the second or third week after the completion of radiotherapy. Doses of nivolumab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment. Relevant outcome measures include disease free survival (2 year post surgery); percutaneous gastronomy dependence (1-year postsurgery); acute and late toxicity; patient-reported Quality of Life measures, locoregional control and distant metastatic control.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Winship Cancer Institute @ Emory University Hospital Midtown
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Cancer Institute
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- UPMC Hillman Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >/= 18 years.
- ECOG performance status of 0 or 1.
- Patients must have newly diagnosed, histologically or cytologically confirmed squamous cell carcinoma or undifferentiated carcinoma of the oropharynx. Patients must have been determined to have resectable oropharyngeal disease. Patients with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not eligible.
- Patients must have intermediate risk factors, as described below as determined by imaging studies (performed < 45 days prior to registration) and complete neck exam, from the skull base to the clavicles. The following imaging is required: CT scan of neck only with IV contrast or MRI. PET scan of HN and chest with IV contrasted CT correlation is encouraged prior to enrollment.
Intermediate risk features: Tobacco <10 pk-yr: T0-3 plus any one of the following: >N2b (> 5 LN's +), N2c/N3, +ENE >1 mm, or + margin (if approved by surgical chair) OR Tobacco >10 pk-yr: T0-3 plus any one of the following: any N2, N3, +ENE >1 mm, or + margin (if approved by surgical chair)
- Patients must have no evidence of distant metastases (M0)
- Patients must have biopsy-proven p16+ oropharynx cancer; the histologic evidence of invasive squamous cell carcinoma may have been obtained from the primary tumor or metastatic lymph node. It is required that patients have a positive p16 IHC (as surrogate for HPV) status from either the primary tumor or metastatic lymph node.
- Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a CLIA approved laboratory.
- No prior radiation above the clavicles.
- Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix, differentiated thyroid cancer, melanoma in-situ (if fully resected), and/or non-melanomatous skin cancer, or clinically negligible in judgement of investigator.
Patients with the following within the last 6 months prior to registration must be evaluated by a cardiologist and / or neurologist prior to entry into the study.
- Congestive heart failure > NYHA Class II
- CVA / TIA
- Unstable angina
- Myocardial infarction (with or without ST elevation)
Patients must have acceptable renal and hepatic function within 4 weeks prior to registration as defined below:
- Absolute neutrophil count ≥1,500/mm3
- Platelets ≥ 100,000/mm3
- Total bilirubin ≤ the upper limit of normal (ULN)
- Calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula: (140-age)*wt(kg)/([Cr]*72). For women the calculation should be multiplied by 0.85
- Women must not be pregnant or breast-feeding. All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy. A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- Patient without intercurrent illness likely to interfere with protocol therapy.
- Patients must not have uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension within 30 days prior to registration.
Exclusion Criteria:
- Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
- Treatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 30 days of first administration of study treatment (subjects with prior radiation, cytotoxic or investigational products < 4 weeks prior to treatment might be eligible after discussion between investigator and sponsor, if toxicities from the prior treatment have been resolved to Grade 1 (NCI CTCAE version 4).
- Known positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. Subjects who test positive for HCV antibody but negative for HCV ribonucleic acid are permitted to enroll.
- Known history of testing positive for human immunodeficiency virus (HIV) and CD4 count < 200 or known acquired immunodeficiency syndrome (AIDS).
- Any Grade 4 laboratory abnormalities.
- History of allergy to study drug components.
- History of severe hypersensitivity reaction to any human monoclonal antibody.
- Prisoners or subjects who are involuntarily incarcerated.
- Subjects compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiotherapy (RT) + Nivolumab Injection
RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week.
Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
|
A fully human anti-programmed death 1 (PD-1) monoclonal antibody
Other Names:
45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From beginning of study treatment (post surgery) up to 3-years
|
The length of time (months) from of beginning of study treatment without local, regional or distant disease recurrence until the appearance of new metastatic lesions.
|
From beginning of study treatment (post surgery) up to 3-years
|
PEG tube dependence
Time Frame: At 1-year post-surgery
|
Presence /absence of enteral feeding tube
|
At 1-year post-surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Score
Time Frame: At 3, 6, 12 and 24 months after completion of treatment
|
The FACT-H&N (version 4)17 consists of a cancer-specific questionnaire, FACT-G, in addition to 12 H&N cancer-specific items (the HN subscale).
FACT-G is a 27-item measure that assesses general cancer quality of life.
The FACT-G contains 4 subscales: physical, social/family, emotional, and functional well-being.
Individuals are asked to indicate how true 27 statements are for them, using the past 7 days as the timeframe.
Responses range from not at all (0), to very much (4) on a 5-point scale.
|
At 3, 6, 12 and 24 months after completion of treatment
|
Locoregional control (LRC)
Time Frame: At 1-year and at 2-year post surgery
|
Identification of disease growth that is present within the area in which it was first located.
|
At 1-year and at 2-year post surgery
|
Distant disease recurrence
Time Frame: At 1-year and at 2 year post-surgery
|
Identification of disease that has spread (metastasized) to areas farther away from where it was first located.
|
At 1-year and at 2 year post-surgery
|
MD Anderson Symptom Inventory for head and neck cancer (MDASI-HN)
Time Frame: At 3, 6, 12 and 24 months after completion of treatment
|
MDASI-HN measures treatment related symptom burden in head and neck cancer patients.
The 20-item MDASI measures both severity and burden of symptoms and their effect on patients' daily activities, using a numeric rating scale of 0-10.
This instrument includes 13 core symptoms and 9 head and neck specific items.
Higher scores indicate superior perception of function.
|
At 3, 6, 12 and 24 months after completion of treatment
|
MD Anderson Dysphagia Inventory (MDADI)
Time Frame: At 3, 6, 12 and 24 months after completion of treatment
|
The MDADI measures swallowing-related quality of life (QOL) in patients with swallowing dysfunction in a 20 - item written questionnaire.
It evaluates the patient's physical (P), emotional (E) and functional (F) perceptions of swallowing dysfunction.
This instrument has been psychometrically validated in head and neck cancer patients.
Higher scores indicate superior perception of swallowing function.
|
At 3, 6, 12 and 24 months after completion of treatment
|
Voice Handicap Index-10 (VHI-10)
Time Frame: At 3, 6, 12 and 24 months after completion of treatment
|
The VHI-10 is a patient self-assessment instrument that quantifies patients' perception of their voice handicap.
It evaluates patient's physical (P), emotional (E), and functional (F) perceptions of voice and has shown to be highly reliable for internal consistency and test-retest stability.
The VHI-10 utilizes a 10-item questionnaire in which the patient circles the response that most accurately reflects his or her own experience on a linear scale (from "never" to "always").
"Always" response is scored 4 points, a "Never" response is scored 0. The remaining options are scored between 1 and 3 points.
The tallied number of points for each of the subscales is computed to a total composite score.
The patient's values are compared to published norms.
|
At 3, 6, 12 and 24 months after completion of treatment
|
Performance Status Scale (PSS-HN)
Time Frame: At 3, 6, 12 and 24 months after completion of treatment
|
The Performance Status Scale (PSS-HN) is a clinician-rated instrument consisting of 3 questions: normalcy of diet, public eating/swallowing, and understandability of speech subscales in patients with head and neck cancer.
Each subscale is rated from 0 to 100, with higher scores indicating better performance.
|
At 3, 6, 12 and 24 months after completion of treatment
|
Modified Barium Swallow (MBS) rating
Time Frame: At 6 and 24 months after completion of treatment
|
Three swallowing outcomes will be rated by the SLP conducting the MBS study and reported by research staff: 1) laryngeal penetration (yes, no); 2) aspiration (no, sensate, silent), and 3) pharyngeal residue (no, < 50%, > 50%).
These have been selected as universal items generally reported by swallowing clinicians that have been shown to significantly predict pneumonia in patients with oropharyngeal cancers.
Prevalence of these dysphagia endpoints will be estimated at each time point.
|
At 6 and 24 months after completion of treatment
|
Overall Survival (OS)
Time Frame: From beginning of study treatment (post surgery) up to 3-years
|
The length of time (in months) from the start of treatment patients remain alive.
|
From beginning of study treatment (post surgery) up to 3-years
|
Adverse Events Related to Treatment
Time Frame: Up to 24 months
|
Number of patients experiencing Adverse Events and Serious Adverse Events (SAE) related to study treatment per Common Terminology Criteria for Adverse Events (CTCAE) v4.0
|
Up to 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor TP53 mutation
Time Frame: At baseline prior to treatment; Up to 5 years
|
Determination of tumor TP53 mutation as measured in serum and/or tissue samples.
The presence of TP53 mutations results in a protein that is less able to control cell proliferation as it is unable to trigger apoptosis in cells with damaged DNA.
|
At baseline prior to treatment; Up to 5 years
|
Determination of Tumor genomics
Time Frame: At baseline prior to treatment; Up to 5 years
|
Determination of tumor genomics, measured in serum and/or tissue samples.
This measure will explore the of DNA sequence and gene expression differences in tumor cells and gene abnormalities may that drive the drives disease growth.
|
At baseline prior to treatment; Up to 5 years
|
Presence of Plasma Cytokines
Time Frame: At baseline prior to treatment; Up to 5 years
|
Determination of cytokines present in plasma samples.
The presence of cytokines in tissues can associated positively or negatively in the development of disease.
|
At baseline prior to treatment; Up to 5 years
|
Antigen-specific immune response to Human papillomavirus (HPV)
Time Frame: At baseline prior to treatment; Up to 5 years
|
Determination of antigen-specific cellular immune response to Human papillomavirus (HPV) measured in serum and/or tissue samples.
|
At baseline prior to treatment; Up to 5 years
|
Determination of oral Human papillomavirus (HPV) DNA
Time Frame: At baseline prior to treatment
|
Determination of oral HPV DNA present/measured in oral tissue samples.
|
At baseline prior to treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Ferris, MD, PhD, UPMC Hillman Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Oropharyngeal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- HCC 18-034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharynx Squamous Cell Carcinoma
-
University of Michigan Rogel Cancer CenterBristol-Myers SquibbActive, not recruitingOropharynx Squamous Cell CarcinomaUnited States
-
Region SkaneRecruitingOropharynx Squamous Cell CarcinomaSweden
-
Sidney Kimmel Comprehensive Cancer Center at Johns...CompletedSquamous Cell Carcinoma of OropharynxUnited States
-
University of ChicagoNational Cancer Institute (NCI)TerminatedTongue Cancer | Stage I Squamous Cell Carcinoma of the Oropharynx | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the OropharynxUnited States
-
University of VirginiaNot yet recruitingSquamous Cell Carcinoma of the OropharynxUnited States
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United Kingdom; Oracle Cancer TrustRecruitingSquamous Cell Carcinoma of the OropharynxUnited Kingdom
-
Joseph CalifanoJohns Hopkins University; NYU Langone Health; Greater Baltimore Medical Center; San Diego Veterans Healthcare System and other collaboratorsCompletedSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Squamous Cell Carcinoma of the OropharynxUnited States
-
CMR Surgical LtdLiverpool University Hospitals NHS Foundation Trust; Sintesi Research S.r.l.RecruitingSquamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma, Unknown PrimaryUnited Kingdom
-
National Cancer Institute (NCI)CompletedStage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditionsUnited States
-
ISA PharmaceuticalsRegeneron PharmaceuticalsActive, not recruitingSquamous Cell Carcinoma of the Oropharynx | HPV16 PositiveNetherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Clinical Trials on Nivolumab Injection
-
University of California, San FranciscoBristol-Myers Squibb; National Cancer Institute (NCI)CompletedHIV/AIDS | Kaposi Sarcoma | ImmunosuppressionUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingMesotheliomaUnited States
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
UNICANCERBristol-Myers SquibbCompletedRecurrent and/or Metastatic Platinum-refractory SCCHNFrance
-
Intergroupe Francophone de Cancerologie ThoraciqueANRS, Emerging Infectious DiseasesCompletedHIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer MetastaticFrance
-
Assistance Publique - Hôpitaux de ParisUnknownCOVID19- Infection With SARS-CoV-2 VirusFrance
-
Tel-Aviv Sourasky Medical CenterRecruiting
-
Melbourne HealthActive, not recruitingHaematological MalignancyAustralia
-
Virogin Biotech Canada LtdRecruitingHepatocellular Carcinoma | Intrahepatic CholangiocarcinomaUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingMelanoma | Metastatic MelanomaFrance